Imaging and cerebrospinal fluid biomarkers in the search for alzheimer's disease mechanisms

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 163-165

  Osorio, R S ^a   Pirraglia, E ^a   Gumb, T ^a   Mantua, J ^a   Ayappa, I ^a   Williams, S ^a   Mosconi, L ^a   Glodzik, L ^a   De Leon, M J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; ApoE4, mechanisms; Biomarkers; Cerebrospinal fluid; Maternal family history; Neuroimaging; Sleep disordered breathing

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; GLUCOSE; TAU PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SYNAPSE; TEMPORAL LOBE; VERY ELDERLY; APNEA HYPOPNEA INDEX; CEREBROSPINAL FLUID ANALYSIS; CONFERENCE PAPER; FAMILY HISTORY; SLEEP DISORDERED BREATHING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 84896711700     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000355063     Document Type: Article

References (20)

1. Braak H, Braak E: Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-278.
2. Fotuhi M, Hachinski V, et al: Changing perspectives regarding late-life dementia. Nat Rev Neurol 2009; 5: 649-658.
3. Amieva H, Le GM, Millet X, et al: Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492-498.
4. de Leon MJ, Convit A, et al: Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positronemission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-10971.
5. Fagan AM, Roe CM, et al: Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
6. Glodzik L, De Santi S, et al: Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiol Aging 2011; 32: 2131-2141.
7. Rowe CC, Ellis KA, et al: Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283.
8. Shim YS, Morris JC: Biomarkers predicting Alzheimer's disease in cognitively normal aging. J Clin Neurol 2011; 7: 60-68.
9. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185.
10. Mosconi L, Brys M, et al: Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 2007; 104: 19067-19072.
11. Glodzik L, De Santi S, et al: Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology. J Alzheimers Dis 2009; 18: 509-513.
12. Glodzik L, Mosconi L, et al: Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol Aging 2011; 33: 1215-1227.
13. Sperling RA, Aisen PS, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
14. Jack CR Jr, Vemuri P, et al: Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011; 68: 1526-1535.
15. Knopman DS, Jack CR Jr, et al: Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012; 78: 1576-1582.
16. Petersen RC, Aisen P, et al: Criteria for mild cognitive impairment due to Alzheimer's disease in the community. Ann Neurol 2013, Epub ahead of print.
17. Pimplikar SW, Nixon RA, et al: Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010; 30: 14946-14954.
18. Jack CR Jr, Knopman DS, et al: Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
19. Huang Y, Potter R, et al: Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. Arch Neurol 2012; 69: 51-58.
20. Thambisetty M, An Y, et al: Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 2013; 73: 422-428.